Covered recipient · General Payments record
ANN E JAMES
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,196.40
- Reported across 87 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $270.99 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $70.68 | 4 |
| Astellas Pharma US Inc | $37.44 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $33.67 | 2 |
| Lundbeck LLC | $26.86 | 1 |
| Novo Nordisk AS | $19.45 | 1 |
| Axsome Therapeutics, Inc. | $18.88 | 1 |
| Teva Pharmaceuticals USA, Inc. | $18.33 | 1 |
| Insulet Corporation | $16.66 | 1 |
| GlaxoSmithKline, LLC. | $15.11 | 1 |
| ABBVIE INC. | $13.91 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.91 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107393573 | CMS |
| Astellas Pharma US Inc | $13.78 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139516595 | CMS |
| Astellas Pharma US Inc | $23.66 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139506937 | CMS |
| Axsome Therapeutics, Inc. | $18.88 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148336607 | CMS |
| GlaxoSmithKline, LLC. | $15.11 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116708023 | CMS |
| Insulet Corporation | $16.66 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116804340 | CMS |
| Lundbeck LLC | $26.86 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146040051 | CMS |
| Novo Nordisk Inc | $19.45 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100441605 | CMS |
| PFIZER INC. | $18.31 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131011128 | CMS |
| PFIZER INC. | $17.27 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131426333 | CMS |
| PFIZER INC. | $19.88 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131999255 | CMS |
| PFIZER INC. | $15.22 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131747470 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.34 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137768625 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.33 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137768627 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.33 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151578751 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.